Atman Health Wins ARPA-H Award to Build Heart Failure AI

Atman Health says in a press release it was selected by ARPA-H to develop an agentic AI system for cardiovascular care, starting with heart failure. The award is part of the ADVOCATE program, which will run for 39 months and focus on chronic cardiovascular disease management in the US. ADVOCATE has more than one lead performer: UpDoc announced a separate award under the same program on the same day.

The system will use a large language model to interpret medical records and communicate with patients by telephone and chat. A deterministic clinical engine will make decisions using more than 9,000 clinical criteria, 9,600 medication and indication pairings, 6,900 dosage adjustment profiles, and over 100 symptom triage flows. It will record the evidence and logic behind each recommendation and check exclusion criteria before proposing medication.

Atman plans to engage with the FDA during the first year, apply for an Investigational Device Exemption at month 12, and target a De Novo submission within 24 months. A single center study operating in shadow mode will precede those regulatory steps.